CAMBRIDGE, MA - Moderna Inc. (NASDAQ:MRNA) announced organizational changes on Monday, expanding the responsibilities of President Stephen Hoge and appointing Ester Banque as Chief Commercial Officer. The biotech company’s stock has surged over 100% in the past year to $52.13, giving it a market capitalization of $20.68 billion.
Hoge will assume operational oversight of the company’s infectious disease, intismeran and rare disease franchises, including cross-functional leadership across research and development, manufacturing and commercial operations, according to a press release statement.
Banque joined Moderna on June 15, 2026, as Chief Commercial Officer. She will lead the company’s global commercial organization and report to Chief Executive Officer Stéphane Bancel. Banque will serve on Moderna’s Executive Committee.
The company said it anticipates potential launches of up to three products in 2027 and 2028, including a flu plus COVID combination vaccine, seasonal flu vaccine and norovirus vaccine. Moderna currently has four approved products in its infectious disease vaccine business.
The company expects clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy and rare genetic disease propionic acidemia therapeutic. Despite the strong stock momentum, InvestingPro analysis reveals analysts don’t expect profitability this year, with the company generating $2.23 billion in revenue over the last twelve months. For deeper insights, investors can access Moderna’s comprehensive Pro Research Report, available for this and 1,400+ other US equities.
Banque previously served as Executive Vice President and President of U.S. Operations at Zoetis, where she led the company’s U.S. commercial operations. She also held the position of Senior Vice President and General Manager of Bristol Myers Squibb’s U.S. Hematology & Cell Therapy Business, where she worked on the launch of five products. Banque spent 25 years at Novartis in various leadership roles across therapeutic areas and geographies.
Banque holds a Bachelor of Science in Chemistry from Universitat Autònoma Barcelona and a Master of Business Administration from Universitat Pompeu Fabra in Spain.
The organizational changes support Moderna’s plan to manage three commercial franchises while advancing its mRNA pipeline and investing in research and early development.
In other recent news, Moderna Inc. announced that their Phase 1/2 study of an investigational cancer vaccine for Lynch syndrome has received authorization from the UK’s Medicines and Healthcare products Regulatory Agency. This vaccine, known as mRNA-4194, targets a condition that significantly increases the risk of several cancer types. Additionally, UBS has reiterated a Neutral rating on Moderna’s stock, maintaining a $45.00 price target. The firm identified the company’s Phase III melanoma trial as a significant catalyst expected in 2026. In corporate governance updates, Moderna’s board approved an amendment to the company’s bylaws, designating federal district courts as the exclusive forum for resolving specific legal complaints. This amendment aligns with recent changes to Delaware’s General Corporation Law. Furthermore, Moderna reported the results of its 2026 Annual Meeting of Stockholders, confirming that a quorum was present for the voting on agenda items.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.Get the bottom line for MRNA plus thousands of other stocks and find your next hidden gem with massive upside.